Alvotech specializes in developing and manufacturing biosimilars, particularly in the European and North American markets. Its competitive position is strengthened by a robust pipeline of products aimed at high-demand therapeutic areas such as oncology and autoimmune diseases, leveraging its proprietary technology platform for efficient production.
Business Overview
Alvotech generates revenue primarily through the sale of biosimilars, which are complex biologic drugs that mimic the efficacy of existing branded therapies. The company benefits from strong pricing power due to the high barriers to entry in the biosimilar market, including regulatory hurdles and the need for extensive clinical trials.
Regulatory approvals for new biosimilars
Partnership announcements for distribution
Market share gains in key therapeutic areas
Clinical trial results impacting product pipeline
Risk Factors
Regulatory changes affecting biosimilar approvals
Technological advancements by competitors that could render existing products obsolete
Increased competition from established pharmaceutical companies entering the biosimilar market
Potential pricing pressure from new entrants
Negative ROA indicating potential inefficiencies in asset utilization
High operating cash flow burn impacting liquidity
Macro Sensitivity
moderate - Alvotech's performance is somewhat tied to healthcare spending, which can be influenced by GDP growth and consumer spending on health.
Interest rates can affect the cost of capital for Alvotech, impacting its ability to finance R&D and production expansion. Higher rates could compress valuation multiples as well.
minimal
Profile
growth - Investors are likely attracted to Alvotech for its potential in the growing biosimilars market.
high - The stock has shown significant volatility, evidenced by a 1-year return of -56.5%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
